Novel antibiotic candidates


YnnoMed is a drug R&D company dedicated to addressing the unmet clinical needs of new antimicrobial agents tackling antimicrobial resistance. With the aid of our in-house developed AI-assisted platform for discovering new drugs, our goal is to design, develop, and distribute first-in-class antimicrobial medicines made in Hong Kong. This technology has been licensed by CUHK academic-led start-up Ynno Med Limited.

  • Novel antibiotic candidates 0
  • Novel antibiotic candidates 1
  • Novel antibiotic candidates 2
Commercialisation opportunities
Problem addressed

By 2050, antimicrobial-resistant infections are projected to cause 10 million deaths worldwide, outracing cancers and burdening healthcare systems across the world. This is further exacerbated by the emergence and spread of multi-drug resistance in bacteria. YnnoMed is therefore developing first-in-class antibiotics against drug-resistant bacteria to provide effective antimicrobial therapeutic options to affected patients.

  • By targeting unprecedented targets that are essential for bacterial survival, YnnoMed has developed series of drug pipelines that possess novel targets, structures, as well as new modes-of-action.
  • The use of in-house AI-assisted plateform for rational drug design significantly accelerated the discovery process.
Key impact
  • First-in-class drug candidates that exhibit potent antimicrobial activity against clinically relevant pathogens (including drug-resistant lineages), low cytotoxicity and low chance of resistance development.
  • The use of in-house AI platform shortens time, streamlines processes, and reduces costs and failure rates involved in pre-clinical stages of drug development.
  • Suppress generation of new antimicrobial resistance.
  • Provide drug design and discovery services to industry partners using our AI-assisted drug discovery platform.
  • Winner for Falling Walls Science Breakthrough of the Year 2023 (Category: Science Start-ups) / Falling Walls Venture 2023
  • Bronze Medal at the “The 48th International Exhibition of Inventions Geneva”
  • Champion at CUHK Innovation Day 2022 cum Elevator Pitch Competition
  • “Innovation Award” at the TechConnect World Innovation Conference and Expo 2019
  • Novel treatment options for antimicrobial resistance
The Chinese University of Hong Kong (CUHK)

Founded in 1963, The Chinese University of Hong Kong (CUHK) is a forward-looking comprehensive research university with a global vision and a mission to combine tradition with modernity, and to bring together China and the West. CUHK teachers and students hail from all around the world. Four Nobel laureates are associated with the university, and it is the only tertiary institution in Hong Kong with recipients of the Nobel Prize, Turing Award, Fields Medal and Veblen Prize sitting as faculty in residence. CUHK graduates are connected worldwide through an extensive alumni network. CUHK undertakes a wide range of research programmes in many subject areas, and strives to provide scope for all academic staff to undertake consultancy and collaborative projects with industry.